Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency

European Journal of Endocrinology

Volumn 163, Issue 6, 2010, Pages 919-924

  Tomalik Scharte, Dorota ^b   Maiter, Dominique ^c   Kirchheiner, Julia ^d   Ivison, Hannah E ^a   Fuhr, Uwe ^b   Arlt, Wiebke ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; ESTROGEN; GLUCOCORTICOID; MIDAZOLAM; MUTANT PROTEIN; OMEPRAZOLE; TOLBUTAMIDE; CYP1A2 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; STEROID; UNSPECIFIC MONOOXYGENASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CASE REPORT; CAUCASIAN; CONGENITAL ADRENAL HYPERPLASIA; DRUG DETOXIFICATION; DRUG METABOLISM; ELECTRON TRANSPORT; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; P450 OXIDOREDUCTASE DEFICIENCY; PHENOTYPE; PRIORITY JOURNAL; SEXUAL DEVELOPMENT; STEROID METABOLISM; STEROIDOGENESIS; ANTLEY BIXLER SYNDROME; GENETICS; LIVER; METABOLISM; MIDDLE AGED; SEX DIFFERENTIATION DISORDER;

ADRENAL HYPERPLASIA, CONGENITAL; ADULT; AGED; ANTLEY-BIXLER SYNDROME PHENOTYPE; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; DISORDERS OF SEX DEVELOPMENT; FEMALE; HUMANS; LIVER; MIDDLE AGED; NADPH-FERRIHEMOPROTEIN REDUCTASE; STEROIDS;

EID: 78649891177     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0764     Document Type: Article

References (32)

1. Arlt W, Walker EA, Draper N, Ivison HE, Ride JP, Hammer F, Chalder SM, Borucka-Mankiewicz M, Hauffa BP, Malunowicz EM, Stewart PM & Shackleton CH. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 2004 363 2128-2135. (doi:10.1016/S0140-6736(04)16503-3)
2. Fluck CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, Jabs EW, Mendonça BB, Fujieda K & Miller WL. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nature Genetics 2004 36 228-230. (doi:10.1038/ng1300) (Pubitemid 38282745)
3. Fukami M, Horikawa R, Nagai T, Tanaka T, Naiki Y, Sato N, Okuyama T, Nakai H, Soneda S, Tachibana K, Matsuo N, Sato S, Homma K, Nishimura G, Hasegawa T & Ogata T. Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. Journal of Clinical Endocrinology and Metabolism 2005 90 414-426. (doi:10.1210/jc.2004-0810)
4. Kelley RI, Kratz LE, Glaser RL, Netzloff ML, Wolf LM & Jabs EW. Abnormal sterol metabolism in a patient with Antley-Bixler syndrome and ambiguous genitalia. American Journal of Medical Genetics 2002 110 95-102. (doi:10.1002/ajmg.10510)
5. Schmidt K, Hughes C, Chudek JA, Goodyear SR, Aspden RM, Talbot R, Gundersen TE, Blomhoff R, Henderson C, Wolf CR & Tickle C. Cholesterol metabolism: the main pathway acting downstream of cytochrome P450 oxidoreductase in skeletal development of the limb. Molecular and Cellular Biology 2009 29 2716-2729. (doi:10.1128/MCB.01638-08)
6. Ribes V, Otto DM, Dickmann L, Schmidt K, Schuhbaur B, Henderson C, Blomhoff R, Wolf CR, Tickle C & Dollé P. Rescue of cytochrome P450 oxidoreductase (Por) mouse mutants reveals functions in vasculogenesis, brain and limb patterning linked to retinoic acid homeostasis. Developmental Biology 2007 303 66-81. (doi:10.1016/j.ydbio.2006.10.032)
7. Porter JA, Ekker SC, Park WJ, von Kessler DP, Young KE, Chen CH, Ma Y, Woods AS, Cotter RJ, Koonin EV & Beachy PA. Hedgehog patterning activity: role of a lipophilic modification mediated by the carboxy-terminal autoprocessing domain. Cell 1996 86 21-34. (doi:10.1016/S0092-8674(00)80074-4) (Pubitemid 26256575)
8. Nebert DW & Russell DW. Clinical importance of the cytochromes P450. Lancet 2002 360 1155-1162. (doi:10.1016/S0140-6736(02)11203-7)
9. Guengerich FP. A malleable catalyst dominates the metabolism of drugs. PNAS 2006 103 13565-13566. (doi:10.1073/pnas.0606333103)
10. Agrawal V, Huang N & Miller WL. Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenetics and Genomics 2008 18 569-576. (doi:10.1097/FPC. 0b013e32830054ac)
11. Hart SN, Wang S, Nakamoto K, Wesselman C, Li Y & Zhong XB. Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenetics and Genomics 2008 18 11-24. (doi:10.1097/FPC.0b013e3282f2f121)
12. Kranendonk M, Marohnic CC, Panda SP, Duarte MP, Oliveira JS, Masters BS & Rueff J. Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase. Archives of Biochemistry and Biophysics 2008 475 93-99. (doi:10.1016/j.abb.2008.04.014)
13. Nicolo C, Fluck CE, Mullis PE & Pandey AV. Restoration of mutant cytochrome P450 reductase activity by external flavin. Molecular and Cellular Endocrinology 2010 321 245-252. (doi:10.1016/j.mce.2010.02.024)
14. Oneda B, Crettol S, Sirot EJ, Bochud M, Ansermot N & Eap CB. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenetics and Genomics 2009 19 877-883. (doi:10.1097/FPC.0b013e32833225e7)
15. Kirchheiner J, Bauer S, Meineke I, Rohde W, Prang V, Meisel C, Roots I & Brockmöller J. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 2002 12 101-109. (doi:10.1097/00008571-200203000-00004)
16. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA & Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. Journal of Biological Chemistry 1994 269 15419-15422.
17. Sachse C, Brockmoller J, Bauer S & Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. American Journal of Human Genetics 1997 60 284-295.
18. Fuhr U, Jetter A & Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clinical Pharmacology and Therapeutics 2007 81 270-283. (doi:10.1038/sj.clpt.6100050)
19. Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, Skott A, Sörgel F, Klaassen T, Kasel D, Harlfinger S, Doroshyenko O, Frank D, Kirchheiner J, Bräter M, Richter K, Gramatté T & Fuhr U. Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metabolism and Disposition 2005 33 1859-1866. (doi:10.1124/dmd.105.005272) (Pubitemid 41697272)
20. Tantcheva-Poor I, Zaigler M, Rietbrock S & Fuhr U. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics 1999 9 131-144.
21. Jetter A, Kinzig-Schippers M, Skott A, Lazar A, Tomalik-Scharte D, Kirchheiner J, Walchner-Bonjean M, Hering U, Jakob V, Rodamer M, Jabrane W, Kasel D, Brockmöller J, Fuhr U & Sörgel F. Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. European Journal of Clinical Pharmacology 2004 60 165-171. (doi:10.1007/s00228-004-0754-z)
22. Chang M, Dahl ML, Tybring G, Gotharson E & Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995 5 358-363. (doi:10.1097/00008571-199512000-00004)
23. Tomalik-Scharte D, Doroshyenko O, Kirchheiner J, Jetter A, Lazar A, Klaassen T, Frank D, Wyen C, Fätkenheuer G & Fuhr U. No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam. European Journal of Clinical Pharmacology 2008 64 1033-1035. (doi:10.1007/s00228-008-0503-9)
24. Dhir V, Ivison HE, Krone N, Shackleton CH, Doherty AJ, Stewart PM & Arlt W. Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P. Molecular Endocrinology 2007 21 1958-1968. (doi:10.1210/me.2007-0066)
25. Pandey AV, Kempna P, Hofer G, Mullis PE & Fluck CE. Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase. Molecular Endocrinology 2007 21 2579-2595. (doi:10.1210/me.2007-0245)
26. Huang N, Agrawal V, Giacomini KM & Miller WL. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. PNAS 2008 105 1733-1738. (doi:10.1073/pnas.0711621105)
27. Gomes AM, Winter S, Klein K, Turpeinen M, Schaeffeler E, Schwab M & Zanger UM. Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics 2009 10 579-599. (doi:10.2217/pgs.09.7)
28. Henderson CJ, Otto DM, Carrie D, Magnuson MA, McLaren AW, Rosewell I & Wolf CR. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. Journal of Biological Chemistry 2003 278 13480-13486. (doi:10.1074/jbc.M212087200)
29. Henderson CJ, Pass GJ & Wolf CR. The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity. Toxicology Letters 2006 162 111-117. (doi:10.1016/j.toxlet.2005.10.016)
30. Parkinson A, Mudra DR, Johnson C, Dwyer A & Carroll KM. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human livermicrosomes and inducibility in cultured human hepatocytes. Toxicology and Applied Pharmacology 2004 199 193-209. (doi:10.1016/j.taap.2004.01.010) (Pubitemid 39208721)
31. Bebia Z, Buch SC, Wilson JW, Frye RF, Romkes M, Cecchetti A, Chaves-Gnecco D & Branch RA. Bioequivalence revisited: influence of age and sex on CYP enzymes. Clinical Pharmacology and Therapeutics 2004 76 618-627. (doi:10.1016/j.clpt.2004.08.021)
32. Perera MA. The missing linkage: what pharmacogenetic associations are left to find in CYP3A? Expert Opinion on Drug Metabolism & Toxicology 2010 6 17-28. (doi:10.1517/17425250903379546)